CoChat

P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough

Open access

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Abstract

Cough is among the most common complaints for which patients worldwide seek medical attention. In a majority of patients with chronic cough (defined as cough of greater than 8 weeks' duration), successful management results from a thorough evaluation and treatment of underlying causes. In a subgroup of patients, however, cough proves refractory to therapeutic trials aimed at known reversible causes of chronic cough. Such patients are appropriately termed as having refractory chronic cough. At present, safe and effective medications are lacking for this challenging patient population. Currently available therapeutic options are usually ineffective or achieve antitussive effect at the expense of intolerable side effects, typically sedation. Fortunately, the past decade has witnessed great progress in elucidating underlying mechanisms of cough. From that knowledge, aided by the development of validated instruments to measure objective and subjective cough-related end points, numerous antitussive drug development programs have emerged. The most active area of inquiry at present involves antagonists of the purinergic P2X receptors. Indeed, four clinical programs (one in Phase 3 and three in Phase 2) are currently underway investigating antagonists of receptors comprised entirely or partially of the P2X3 subunit as potential antitussive medications. Herein we review the foundation on which P2X receptor antagonists were developed as potential antitussive medications and provide an update on current clinical trials.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00408-020-00377-8

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 69 references

Cited by

See all 57

Metadata

Authors
Dicpinigaitis, P. V., McGarvey, L. P., & Canning, B. J.
Affiliations
  • Albert Einstein College of Medicine (US)
  • Queen's University Belfast (GB)
  • Johns Hopkins University (US)
Corresponding author
Dicpinigaitis, Peter V.
Venue
Lung
Published
2020-07-13
Volume
198
Issue
4
Pages
609-616
ISSN
  • 0341-2040 (ISSN-L)
  • 1432-1750
OpenAlex
W3043367146
Cited by
57
References
67
Citations by year
2026: 6 · 2025: 5 · 2024: 8 · 2023: 11 · 2022: 7 · 2021: 14 · 2020: 6
FWCI
1.33
Type
journal article
Language
en
Open access
Licence
Locations
  • Lung (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (Queen's University Belfast) (submittedVersion, other-oa)
Funders
National Heart, Lung, and Blood Institute (R01HL141251)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory and Cough-Related Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
Keywords
P2X3 receptor antagonist, antitussive agents, chronic cough, refractory chronic cough, purinergic receptors, cough mechanism, clinical trials, drug development
MeSH terms
Benzenesulfonamides, Ageusia, Antitussive Agents, Chronic Disease, Clinical Trials as Topic, Cough, Humans, Imidazoles, Piperidines, Pyridines, Pyrimidines, Sulfonamides, Receptors, Purinergic P2X3, Purinergic P2X Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough. https://app.cochat.ai/papers/10.1007/s00408-020-00377-8
The paper
Dicpinigaitis, P. V., McGarvey, L. P., & Canning, B. J. (2020). P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough. Lung. https://doi.org/10.1007/s00408-020-00377-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.